Wednesday, April 18, 2018 9:57:21 PM
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.(BPTH), , a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that data from pre-clinical studies supporting the potential of prexigebersen (BP1001, liposomal Grb2 antisense), in the treatment of solid tumors in gynecologic malignancies were presented in a poster at the annual meeting of the American Association for Cancer Research (AACR), which took place in Chicago, IL.
The poster titled, “Grabbing GRB2: The use of Liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies,” was presented by Olivia D. Lara, M.D., University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology during the Experimental and Molecular Therapeutics Poster Session. The data summarize results from studies investigating the expression of GRB2 in a series of in vitro experiments in high-grade serous (HGSC) and uterine (UC) carcinoma models. The study also examined the biological effects of prexigebersen in HGSC mice models (OVCAR 5), first in a dose-defining experiment then in combination with standard dose paclitaxel.
The data showed there was an eighty-six percent (86%) decrease in tumor burden (p<0.05), and multinodular burden (p<0.01) in the combination prexigebersen/paclitaxel group compared to control. In addition, there was no apparent toxicity with mice on combination therapy losing less weight than the paclitaxel-only group (P = 0.005).
“We are delighted to present these very encouraging findings at this year’s AACR before an audience of the world’s leading cancer researchers and clinicians,” stated Peter H. Nielsen, chief executive officer of Bio-Path Holdings(BPTH). “Our research continues to suggest that prexigebersen-based combination therapy may offer an attractive method for targeting solid tumors and these findings establish the GRB2/GAB2 complex as an important target for prexigebersen. We look forward to advancing this promising therapy in gynecologic and other solid tumor cancers and plan to initiate first-in-human studies as early as the end of this year.”
Recent BPTH News
- Bio-Path Holdings Announces Publication in Biomedicines • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 09:10:15 PM
- Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:15:26 PM
- Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 11:30:23 AM
- Bio-Path Holdings Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:41:00 PM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:14:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:10:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:38:40 PM
- Bio-Path Holdings Provides Clinical Update and Expansion Plans • GlobeNewswire Inc. • 07/08/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/17/2024 12:00:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/17/2024 04:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:18:17 AM
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/11/2024 09:30:47 PM
- Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/05/2024 09:46:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:20:35 PM
- Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM